source
- China’s $522 bn biotech push fuels US competition and partnership opportunitiesChinese biotech is entering a rapid growth phase, with the government’s new five-year plan targeting about $522 billion in revenue by 2030 and aiming for at least 25% of first-in-class drugs worldw…
- Amgen's Sjögren's drug dazodalibep meets primary endpoint in Phase 3 trialAmgen reported that its experimental therapy for Sjögren's disease, dazodalibep, achieved the primary goal in a late‑stage study. The Phase 3 OASIZ 301 trial enrolled roughly 621 patients with mod…